Peptide T and related peptides in the treatment of HTLV-1 myelopathy and multiple sclerosis
AssigneeReed MacFadden, Ltd.
InventorsDouglas K. MacFadden, Peter L. Carlen, Penelope Reed Doob
Life of this patent
Estimating the term…
Abstract
A composition useful in treating Multiple Sclerosis and HTLV-1 myelopathy in humans comprises: i) a peptide having as its active portion, an amino acid sequence of the formula: -Thr-Thr-Asn-Tyr-Thr-; and ii) a pharmaceutically acceptable carrier for said peptide.
Claims4
A method for alleviating neurological, cognitive or motor symptoms of myelopathy associated with multiple sclerosis or HTLV-1 in humans, comprising the parenteral administration on a daily basis of a composition comprising:
- i) a peptide in an amount effective to alleviate neurological, cognitive or motor symptoms of myelopathy associated with multiple sclerosis or HTLV-1, said peptide having the formula:
- D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-amide (SEQ ID NO:1);
- ii) a pharmaceutically acceptable carrier for the parenteral administration of said peptide.
A method for alleviating neurological, cognitive or motor symptoms of myelopathy associated with multiple sclerosis or HTLV-1 in humans, comprising the intranasal administration on a daily basis of a composition comprising:
- i) a peptide in an amount effective to alleviate neurological, cognitive or motor symptoms of myelopathy associated with multiple sclerosis or HTLV-1, said peptide having the formula:
- D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-amide (SEQ ID NO:1);
- ii) a pharmaceutically acceptable carrier for the intranasal administration of said peptide.
Dependencies are inferred from the claim text.